Topic
Xanthone
About: Xanthone is a research topic. Over the lifetime, 1639 publications have been published within this topic receiving 25870 citations. The topic is also known as: 9-oxo-xanthene & Diphenyline ketone oxide.
Papers published on a yearly basis
Papers
More filters
TL;DR: One new prenylated xanthone named banfoxanthone is isolated from Garcinia ovalifolia and others species of genus Garcinia appear to be useful as chemotaxonomic markers in Garcinia.
Abstract: A detailed chemical investigation of the secondary metabolites from the extract of the stem bark of Garcinia ovalifolia led to the isolation of one new prenylated xanthone named banfoxanthone and five known compounds, namely friedeline, canophyllal, ovalifoloneA, 3-methoxycheffouxanthone, endodesmiadol. Prenylated xanthones isolated from Garcinia ovalifolia and others species of genus Garcinia appear to be useful as chemotaxonomic markers in Garcinia.
TL;DR: In this article, the 2,2′-diiodoketone is oxidized to the corresponding ketones by refluxing with Cu powder in N,N-dimethylformamide (DMF).
Abstract: Bis-(4-nitrophenyl) methane and derivatives can be oxidized to the corresponding ketones by refluxing with Cu powder in N,N-dimethylformamide (DMF). Further reaction of the 2,2′-diiodoketone, under the same conditions, leads to the title xanthone.
Patent•
15 Jun 2018
TL;DR: The xanthone compound C doitunggarcinone L can remarkably inhibit proliferation of a human prostate cancer cell PC-3, a human cervical carcinoma cell, a non-small cell lung cancer cell A549 and a human colon cancer cell HT-29, has the function of inhibiting proliferation of tumor cells, is expected to serve as an active ingredient for preparing the anti-tumor medicine and has a medicinal prospect.
Abstract: The invention discloses medicine application of a xanthone compound C. The xanthone compound C has the chemical structure as shown in formula 1, and has the chemical name of doitunggarcinone L. The medicine application means taking the xanthone compound C or at least one of an aquo-complex, a pharmaceutically acceptable salt, a tautomer, a stereisomer and a precursor compound of the xanthone compound C as an active ingredient for preparing an anti-tumor medicine. Experiments show that the xanthone compound C doitunggarcinone L can remarkably inhibit proliferation of a human prostate cancer cell PC-3, a human cervical carcinoma cell, a human non-small cell lung cancer cell A549 and a human colon cancer cell HT-29, has the function of inhibiting proliferation of tumor cells, is expected to serve as an active ingredient for preparing the anti-tumor medicine and has a medicinal prospect.
Patent•
09 Oct 2018
TL;DR: The 7-nitro-1,3-dyhydroxy xanthone has new anti-tumor activity as discussed by the authors, and therefore, it has new application in the aspect of anti-cancer medicines.
Abstract: The invention provides a 7-nitro-1,3-dyhydroxy xanthone. The 7-nitro-1,3-dyhydroxy xanthone has new anti-tumor activity, and therefore, the 7-nitro-1,3-dyhydroxy xanthone has new application in the aspect of anti-cancer medicines, especially the aspect of anti-lung-cancer medicines.
DOI•
24 Aug 2018
TL;DR: In this article, the xanthone was isolated from the defatted fraction of the aqueous methanolic stem-bark extract and the cytotoxic activity was evaluated using the brine shrimp lethality test of stem bark extract.
Abstract: In this study, the crude, defatted extracts and the pure isolated xanthone (1,8-dihydroxy-2,5-dimethoxyxanthone) were screened in vitro for cytotoxicity activities, the xanthone was isolated from the defatted fraction of the aqueous methanolic stem-bark extract. The cytotoxic activity was evaluated using the brine shrimp lethality test of stem bark extract and the isolated compound, 1,8-dihydroxy-2,5-dimethoxyxanthone gave LC50 values less than 200 μg/mL, indicating a high pharmacological potential and could serve as anticancer agent.